| PD-L1 | Programmed cell death ligand-1 |
| PD-1 | Programmed cell death protein-1 |
| HNSCC | Head and neck squamous cell carcinoma |
| siRNA | Small interfering ribonucleic acid |
| EMT | Epithelial–mesenchymal transition |
| FDA | Food and Drug Administration |
| PD-L2 | Programmed cell death ligand 2 |
| IFN | Interferon |
| APC | Antigen-presenting cell |
| PCI | Pittsburgh Cancer Institute |
| NT | Nontargeting |
| KD | Knockdown |
| CV | Control vector |
| OE | Overexpression |
| RAC2 | Gene encoding for the small Rho-GTPase Rac2 |
| ARGHDIA | Gene encoding for Rho-GDP-dissociation inhibitor 1 |
| PAK4 | Gene encoding for serine/threonine-protein kinase PAK 4 |
| ITGA4 | Gene encoding for integrin alpha 4 |
| MMP9 | Gene encoding for matrix-metalloproteinase 9 |
| RHO | Gene encoding for the small Rho-GTPase Rho |
| qPCR | Quantitative polymerase chain reaction |
| DMEM | Dulbecco’s modified Eagle’s medium |
| FCS | Fetal calf serum |
| EDTA | Ethylenediaminetetraacetic acid |
| DAB | 3,3′-Diaminobenzidine |
| PBS | Phosphate buffered saline |
| PVDF | Polyvinylidene fluoride |
| SDS-PAGE | Sodium dodecyl sulfate polyacrylamide gel electrophoresis |
| γ | Gamma |
| SD | Standard deviation |